DeepSight™ Technology, a San Francisco-based augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, raised $25 million Series A.
The round was led by Deerfield Management Company, a healthcare investment firm, with additional funding from Wing, Alter Venture Partners, and Time BioVentures.
This Series A financing in a novel medical device technology to help advance a range of imaging procedures.
Company: DeepSight™ Technology, Inc.
Round: Series A
Funding Month: October 2021
Lead Investors: Deerfield Management Company
Additional Investors: Wing, Alter Venture Partners, and Time BioVentures
Company Website: https://deepsightinc.com/
Software Category: Diagnostic medical imaging
About the Company: Founded in 2019, DeepSight Technology's vision is to reinvent diagnostic imaging. DeepSight's proprietary sensor technology delivers a quantum leap in performance that vastly extends the range of diagnostic medical ultrasound to benefit public health and well-being. DeepSight is augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, using patented hardware, software, and AI algorithms to deliver 100 times higher sensitivity than other ultrasound systems in the market. Existing ultrasound technologies are limited by sensitivity, depth penetration, and clarity. DeepSight improves ultrasound image quality and more than doubles the effective range when compared to conventional technologies. DeepSight is headquartered in the San Francisco Bay Area with offices in St. Louis, Missouri.